Pure Biologics Spólka Akcyjna (PUR) - Total Assets
Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) holds total assets worth zł1.33 Million PLN (≈ $366.04K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check PUR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Pure Biologics Spólka Akcyjna - Total Assets Trend (2016–2024)
This chart illustrates how Pure Biologics Spólka Akcyjna's total assets have evolved over time, based on quarterly financial data. Explore PUR long-term investments to assets to see how much of total assets are deployed in long-term investments.
Pure Biologics Spólka Akcyjna - Asset Composition Analysis
Current Asset Composition (December 2024)
Pure Biologics Spólka Akcyjna's total assets of zł1.33 Million consist of 89.9% current assets and 10.1% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 13.4% |
| Accounts Receivable | zł1.63 Million | 69.7% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł117.00K | 5.0% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Pure Biologics Spólka Akcyjna's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pure Biologics Spólka Akcyjna market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pure Biologics Spólka Akcyjna's current assets represent 89.9% of total assets in 2024, an increase from 52.8% in 2016.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, down from 23.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 42.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 69.7% of total assets.
Pure Biologics Spólka Akcyjna Competitors by Total Assets
Key competitors of Pure Biologics Spólka Akcyjna based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Pure Biologics Spólka Akcyjna - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.67 | 0.86 |
| Quick Ratio | 0.06 | 0.67 | 0.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł-19.40 Million | zł-5.24 Million | zł-1.68 Million |
Pure Biologics Spólka Akcyjna - Advanced Valuation Insights
This section examines the relationship between Pure Biologics Spólka Akcyjna's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 3.35 |
| Asset Growth Rate (YoY) | -89.7% |
| Total Assets | zł2.34 Million |
| Market Capitalization | $7.86 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pure Biologics Spólka Akcyjna's assets at a significant premium (3.35x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Pure Biologics Spólka Akcyjna's assets decreased by 89.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pure Biologics Spólka Akcyjna (2016–2024)
The table below shows the annual total assets of Pure Biologics Spólka Akcyjna from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł2.34 Million ≈ $644.83K |
-89.70% |
| 2023-12-31 | zł22.74 Million ≈ $6.26 Million |
-31.12% |
| 2022-12-31 | zł33.01 Million ≈ $9.08 Million |
-30.05% |
| 2021-12-31 | zł47.19 Million ≈ $12.99 Million |
+149.13% |
| 2020-12-31 | zł18.94 Million ≈ $5.21 Million |
-13.05% |
| 2019-12-31 | zł21.79 Million ≈ $6.00 Million |
+231.17% |
| 2018-12-31 | zł6.58 Million ≈ $1.81 Million |
+395.97% |
| 2017-12-31 | zł1.33 Million ≈ $365.03K |
+39.35% |
| 2016-12-31 | zł951.82K ≈ $261.95K |
-- |
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more